ClinicaliQ Trial Snapshot
- HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — Recruiting • Phase II • NCT07575308.
- A trial testing ALN-6400 injections to reduce heavy menstrual bleeding in women and girls with von Willebrand disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB Conditions: Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) Interventions: ALN-6400 Lead Sponsor: Alnylam Pharmaceuticals Planned Enrollment: 24 participants